Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Purchased by Vestal Point Capital LP

Vestal Point Capital LP increased its holdings in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 41.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,200,000 shares of the company's stock after purchasing an additional 350,000 shares during the period. Vestal Point Capital LP owned 3.63% of Lexeo Therapeutics worth $7,896,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of LXEO. Janus Henderson Group PLC grew its position in Lexeo Therapeutics by 15.3% in the fourth quarter. Janus Henderson Group PLC now owns 4,339,254 shares of the company's stock valued at $28,508,000 after acquiring an additional 576,059 shares in the last quarter. Altium Capital Management LLC purchased a new position in shares of Lexeo Therapeutics in the fourth quarter valued at $2,665,000. Point72 Asset Management L.P. boosted its stake in shares of Lexeo Therapeutics by 102.5% in the fourth quarter. Point72 Asset Management L.P. now owns 750,235 shares of the company's stock valued at $4,937,000 after purchasing an additional 379,828 shares during the period. DAFNA Capital Management LLC grew its holdings in Lexeo Therapeutics by 56.9% during the 4th quarter. DAFNA Capital Management LLC now owns 393,083 shares of the company's stock valued at $2,586,000 after purchasing an additional 142,500 shares in the last quarter. Finally, Privium Fund Management B.V. purchased a new stake in Lexeo Therapeutics during the 4th quarter worth $909,000. Institutional investors and hedge funds own 60.67% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. HC Wainwright cut their price objective on shares of Lexeo Therapeutics from $23.00 to $15.00 and set a "buy" rating on the stock in a report on Friday, May 16th. Chardan Capital dropped their target price on Lexeo Therapeutics from $22.00 to $20.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Royal Bank of Canada cut their price target on Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 25th. Finally, Leerink Partners reduced their price target on Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating for the company in a report on Monday, March 24th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Lexeo Therapeutics presently has an average rating of "Buy" and a consensus target price of $20.20.

Lexeo Therapeutics Stock Up 0.7%

NASDAQ:LXEO traded up $0.02 during mid-day trading on Thursday, reaching $3.08. The stock had a trading volume of 323,258 shares, compared to its average volume of 487,744. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. The company has a market capitalization of $102.25 million, a price-to-earnings ratio of -0.97 and a beta of 1.27. Lexeo Therapeutics, Inc. has a 1-year low of $1.45 and a 1-year high of $19.50. The stock's 50 day simple moving average is $3.09 and its two-hundred day simple moving average is $4.87.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.19). Equities analysts anticipate that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current year.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.